Muthu Kumaran, MD
Medical Oncology · Little Rock, ARNPI 1003080854
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Gilead at 24.6% of the total. Among medical oncology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $823.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$48K
- Geron Corporation$22K
- Sanofi-aventis U.S. LLC$20K
- ADC Therapeutics America, Inc.$19K
- Incyte Corporation$17K
- Agios Pharmaceuticals, Inc.$11K
- plus $56K from 15 others
Across 78 payments — averaging $2821.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$129K
- Gilead$45K
- Sanofi US Services Inc.$23K
- Alnylam Pharmaceuticals Inc.$14K
- Incyte Corporation$7K
- Kadmon Corporation LLC$2K
- plus $800 from 1 others
What the payments were for
- Consulting fees$113,25159%
- Speaking & faculty fees$50,56326%
- Travel & lodging$23,57912%
- Food & beverage$5,8723%
- Education$1860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 62 | $47,606 |
| Geron Corporation | 17 | $22,138 |
| Sanofi-aventis U.S. LLC | 23 | $20,205 |
| ADC Therapeutics America, Inc. | 11 | $19,288 |
| Incyte Corporation | 20 | $17,170 |
| Agios Pharmaceuticals, Inc. | 14 | $10,910 |
| Sobi, Inc | 10 | $10,590 |
| Sanofi | 11 | $8,397 |
| Daiichi Sankyo Inc. | 10 | $7,088 |
| Jazz Pharmaceuticals Inc. | 13 | $6,154 |
| Acrotech Biopharma Inc. | 11 | $5,962 |
| Syndax Pharmaceuticals, Inc. | 8 | $5,256 |
| Genmab U.S., Inc. | 8 | $3,172 |
| E.r. Squibb & Sons, L.L.C. | 4 | $3,128 |
| TG Therapeutics, Inc. | 2 | $2,036 |
| Novartis | 1 | $1,485 |
| AstraZeneca | 5 | $1,437 |
| Servier Pharmaceuticals LLC | 1 | $1,125 |
| Astellas Pharma US Inc | 2 | $145 |
| Bristol Myers Squibb | 1 | $125 |
| Amgen | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$193,451 in reported general payments places this provider in the 95th percentile of 20 medical oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IdhifaEnasidenib Mesylate | 21 | $657,021 |
| PromactaEltrombopag Olamine | 28 | $474,300 |
| RezurockBelumosudil Mesylate | 12 | $369,348 |
| SprycelDasatinib | 22 | $341,520 |
| JakafiRuxolitinib Phosphate | 27 | $321,946 |
| OnuregAzacitidine | 13 | $320,631 |
| VenclextaVenetoclax | 53 | $304,866 |
| ImbruvicaIbrutinib | 16 | $244,619 |
| BrukinsaZanubrutinib | 21 | $221,406 |
| CalquenceAcalabrutinib Maleate | 13 | $199,215 |
| InqoviDecitabine/Cedazuridine | 24 | $189,292 |
| BosulifBosutinib | 11 | $154,859 |
| XareltoRivaroxaban | 23 | $17,611 |
| Bexarotene | 12 | $17,280 |
| EliquisApixaban | 19 | $15,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Sprycel, Onureg | $3,128 | $662,15235 claims |
| Bristol Myers SquibbIdhifa | $125 | $657,02121 claims |
| NovartisPromacta | $1,485 | $474,30028 claims |
| Sanofi-aventis U.S. LLCRezurock | $20,205 | $369,34812 claims |
| Incyte CorporationJakafi | $17,170 | $321,94627 claims |
| AstraZenecaCalquence | $1,437 | $199,21513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 20 medical oncology providers in Arkansas.
Other medical oncology in Little Rock
- Cesar Gentille SanchezLittle Rock$29K
- Ankur VarmaLittle Rock$248
- Laura HutchinsLittle Rock$150
- Sunilkumar KakadiaHot Springs$31K
- Stephen ToothakerSearcy$19K
- Ryan KochSearcy$15K
- Zaki SammanFort Smith$9K
- Kristen SagerMena$8K
- Chen HuangHarrison$5K
- William RobertsonSearcy$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.